JBIO
Jade Biosciences, Inc.
NASDAQ · Healthcare · Biotechnology · US
$13.83
+2.67%Sep 30, 2026, 11:00 UTC
Jade Biosciences announced preclinical data characterizing JADE301, a half-life-extended anti-IFN-β monoclonal antibody in development for dermatomyositis, at EADV 2026.
Source:Aug 10, 2026, 11:00 UTC
Jade Biosciences reported its financial results for the second quarter ending June 30, 2026, with cash, cash equivalents, and investments of $461 million as of that date, expected to provide runway into the fourth quarter of 2028.
Source:Jun 26, 2026, 00:00 UTC
Jade Biosciences, Inc. appointed Mark Eisner as a Class I director and member of the Nominating and Corporate Governance Committee, effective June 25, 2026.
Jun 12, 2026, 00:00 UTC
Michael Amoroso resigned from the Board of Directors of Abeona Therapeutics Inc., effective June 11, 2026.
Jun 4, 2026, 02:58 UTC
Jade Biosciences priced a public offering of 10,000,000 shares of common stock at $15.00 per share, expecting gross proceeds of $150.0 million.
Jun 2, 2026, 01:08 UTC
Jade Biosciences announced interim results from a Phase 1 healthy volunteer study of JADE101, showing rapid and durable reductions in serum IgA, supporting advancement into patient studies for IgA nephropathy.
Source: